-
Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China
17 Feb 2026 16:50 GMT
Introduction
Non-small cell lung cancer (NSCLC) accounts for approximately 85% … SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, … advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival …
-
Real-World Outcomes and Safety of PD-1 Blockade Rechallenge Strategies After Prior Immunotherapy in Advanced NSCLC: A Retrospective Cohort Study
17 Feb 2026 16:50 GMT
… patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis … immunotherapy treated advanced non-small cell lung cancer: a retrospective exploratory … immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental …
-
Lilly’s Retevmo boosts event-free survival in early-stage NSCLC
17 Feb 2026 11:33 GMT
… during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC).
In the LIBRETTO-432 trial … adjuvant therapy in this population.
NSCLC accounts for about 85% of … in locally advanced or metastatic NSCLC, advanced or metastatic medullary thyroid …
-
Clinicopathological and Genomic Analysis of SMARCA4-Deficient Non-Small Cell Lung Cancer: A Retrospective Cohort Study
16 Feb 2026 13:41 GMT
… and aggressive subtype of non-small cell lung cancer (NSCLC) characterized by loss of … and immunotherapy resistance in non-small cell lung cancer: the role of KEAP1 … efficacy in SMARCA4-deficient non-small cell lung cancer. Transl Lung Cancer Res …
-
<![CDATA[Adjuvant Selpercatinib Improves EFS in Early-Stage RET+ NSCLC]]>
16 Feb 2026 22:37 GMT
… patients with RET fusion-positive NSCLC who have completed prior definitive … known additional oncogenic drivers in NSCLC, evidence of small cell lung … or radiation in participants with non-small cell lung cancer (NSCLC) (LIBRETTO-432). ClinicalTrials.gov. …
-
NSCLC Survival Not Tied to Common Drugs + Immunotherapy Use
16 Feb 2026 09:13 GMT
… in veterans with stage IV non-small cell lung cancer (NSCLC) who received immune checkpoint inhibitors … with newly diagnosed stage IV NSCLC who received first- or second … treatment outcomes in stage IV NSCLC, and prior reports of such …
-
Johnson & Johnson's New FDA Approval Lets Lung Cancer Patients Switch To Monthly Dosing Sooner
17 Feb 2026 17:29 GMT
… receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC), monthly dosing delivers consistent … factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
Rybrevant Faspro is approved … untreated, EGFR-mutated advanced NSCLC.
The study showed a …
-
Lilly's rare cancer drug Retevmo looks to broaden reach with adjuvant trial win
17 Feb 2026 16:11 GMT
… (II-IIIA) RET fusion-positive non-small cell lung cancer (NSCLC). The twice-daily oral medication … the patient population, Lilly said.
NSCLC accounts for about 85% of …
-
Osimertinib ± Savolitinib in MET-EGFR NSCLC Trial
15 Feb 2026 10:40 GMT
… in the treatment landscape for non-small cell lung cancer (NSCLC), specifically targeting patients harboring … resistance and disease progression.
NSCLC remains the leading cause of … and molecular stratification in managing NSCLC. The identification of MET …
-
Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients
17 Feb 2026 13:00 GMT
… for patients with early-stage non-small cell lung cancer.
Lung Cancer Trial Shows Benefit … patients with RET fusion-positive non-small cell lung cancer.
This trial is the first …
About
© 1995-2026